CXCL8 Antibody

What is CXCL8 and why are antibodies against it important in research?

CXCL8, also known as Interleukin-8 (IL-8), is a pro-inflammatory CXC chemokine synthesized as a 99 amino acid precursor protein that gets processed into different isoforms. The most common forms are 72 or 77 amino acids in length, with IL-8(72) being the predominant form in adults expressed by monocytes, macrophages, epithelial cells, and fibroblasts in response to inflammatory stimuli . The IL-8(77) isoform is secreted primarily by endothelial cells and is considered a less potent neutrophil activator than other forms .

CXCL8 is essential for activating and recruiting neutrophils to sites of inflammation and can influence T cell migration . It signals through G-protein coupled receptors CXCR1 and CXCR2 . Beyond its inflammatory functions, CXCL8 is associated with tumor angiogenesis and metastasis, with transcripts often upregulated in tumors .

Antibodies against CXCL8 are valuable research tools that enable:

• Detection and quantification of CXCL8 in various experimental systems

• Blocking CXCL8 activity in functional assays to determine its role in biological processes

• Visualization of CXCL8 expression patterns in tissues and cells

• Development of diagnostic and potential therapeutic approaches

How do I select the appropriate CXCL8 antibody for my specific research application?

Selecting the optimal CXCL8 antibody requires consideration of several key factors:

• Application compatibility: Different antibodies are optimized for specific techniques:

  • For flow cytometry: Consider pre-titrated antibodies like clone 8CH conjugated to fluorochromes such as APC, with established parameters (Excitation: 633-647 nm; Emission: 660 nm) .

  • For Western blot: Antibodies like clone 6217 have been validated to detect bands at approximately 10 kDa in stimulated cells .

  • For immunohistochemistry: Antibodies such as MAB208 have been validated at specific concentrations (e.g., 10 μg/mL) for tissue staining .

  • For ELISA: Consider matched antibody pairs, such as MAB2081 (capture) and MAB2082 (detection) .

• Clone specificity: Different monoclonal antibodies recognize distinct epitopes. For example, clone 8CH reacts with human IL-8 (CXCL8) with specific binding characteristics .

• Validated applications: Choose antibodies with documented validation for your specific application. For instance, clone 8CH has been validated for intracellular staining followed by flow cytometric analysis .

• Isoform recognition: Determine whether the antibody recognizes specific or all isoforms of CXCL8.

• Species reactivity: Most CXCL8 antibodies target human CXCL8, though some may cross-react with other species. Note that rodents lack a direct IL-8/CXCL8 gene counterpart .

• Functional properties: For neutralization studies, select antibodies with demonstrated neutralizing activity, such as those with established ND50 values (e.g., 0.08-0.4 μg/mL in the presence of 20 ng/mL recombinant human CXCL8) .

What are the fundamental protocols for validating a new CXCL8 antibody in my laboratory?

A comprehensive validation strategy for CXCL8 antibodies should include:

• Positive control testing: Use cells or tissues known to express CXCL8:

  • Stimulate THP-1 human acute monocytic leukemia cells with 200 nM PMA and 10 μg/mL LPS for 24 hours followed by 3 hours to induce CXCL8 expression .

  • Human PBMCs treated with LPS (1 μg/mL for 24 hours) provide another reliable positive control .

• Western blot validation: Look for specific bands at the expected molecular weight:

  • CXCL8 should appear at approximately 8-11 kDa under reducing conditions .

  • Compare stimulated (+) versus unstimulated (-) cells to confirm specificity .

• Flow cytometry validation:

  • Use intracellular staining protocols with appropriate fixation and permeabilization.

  • Titrate antibody concentration (starting at 5 μL/0.015 μg per test for 10^5-10^8 cells in 100 μL) .

  • Include isotype controls matching the primary antibody's isotype.

• Immunofluorescence/immunohistochemistry validation:

  • Test multiple fixation and antigen retrieval methods.

  • Include positive control tissues known to express CXCL8.

  • Evaluate both signal intensity and expected subcellular localization patterns.

• ELISA performance assessment:

  • Generate standard curves using recombinant human CXCL8 protein.

  • Determine assay sensitivity, dynamic range, and reproducibility.

  • Perform spike and recovery experiments to assess matrix effects.

• Functional validation for neutralizing antibodies:

  • Use chemotaxis assays with CXCR2-expressing cells (e.g., BaF3 transfected with human CXCR2) .

  • Confirm dose-dependent inhibition of CXCL8-induced migration.

• Cross-reactivity assessment: Test against related chemokines to ensure specificity.

How can I optimize CXCL8 detection in intracellular staining for flow cytometry?

Optimizing intracellular CXCL8 staining requires attention to several critical parameters:

• Cell stimulation protocol:

  • For optimal CXCL8 induction in monocytic cells, use 200 nM PMA combined with 10 μg/mL LPS for 24 hours (signaling initiation) followed by 3 hours (protein accumulation) .

  • For PBMCs, LPS treatment (1 μg/mL) for 24 hours has been shown to effectively induce CXCL8 .

• Protein transport inhibition:

  • Add Brefeldin A (5-10 μg/mL) or Monensin (2-3 μM) during the final 4-6 hours of stimulation to block secretion and allow intracellular accumulation.

  • Timing is critical: too short exposure won't allow sufficient accumulation, while too long exposure may affect cell viability.

• Fixation and permeabilization optimization:

  • Test multiple commercial fixation/permeabilization kits to determine optimal epitope preservation.

  • For the 8CH clone, evaluate both formaldehyde/saponin-based and methanol-based permeabilization protocols .

• Antibody titration and staining conditions:

  • Perform a titration series (typically starting at 5 μL/0.015 μg per test for 10^5-10^8 cells) .

  • Optimize incubation time and temperature (typically 30 min at 4°C or room temperature).

  • Include proper washing steps to reduce background.

• Panel design considerations:

  • When using APC-conjugated antibodies (Ex: 633-647 nm; Em: 660 nm), avoid fluorochromes with significant spectral overlap .

  • Include appropriate markers to identify target cell populations.

• Controls:

  • Unstimulated cells as negative controls

  • Isotype controls matching the primary antibody's isotype and fluorochrome

  • Fluorescence-minus-one (FMO) controls for proper gating

  • Single-stained compensation controls

• Data analysis strategies:

  • Use biexponential scaling for proper visualization of populations

  • Consider both percentage of positive cells and mean/median fluorescence intensity

  • For heterogeneous samples, analyze CXCL8 expression within specific cell subsets

What are the key considerations for designing neutralization experiments with anti-CXCL8 antibodies?

Designing robust neutralization experiments requires careful attention to experimental parameters:

• Antibody selection and characterization:

  • Choose validated neutralizing antibodies with known activity profiles.

  • The 6217 clone has demonstrated neutralizing activity with an ND50 (neutralization dose for 50% inhibition) of 0.08-0.4 μg/mL in the presence of 20 ng/mL recombinant human CXCL8 .

• Experimental design components:

  • Establish a full dose-response curve for both CXCL8 and the neutralizing antibody.

  • Include properly matched isotype controls (e.g., IgG2a for K097F7, IgG2b for 152254) .

  • Pre-incubate antibody with CXCL8 before adding to cells to allow binding.

  • Include positive controls using known CXCL8 pathway inhibitors.

• Functional readout selection:

  • Chemotaxis assays: BaF3 mouse pro-B cells transfected with human CXCR2 provide a sensitive system for measuring CXCL8-induced migration .

  • Neutrophil activation: Measure calcium flux, respiratory burst, or degranulation.

  • Intracellular signaling: Phosphorylation of downstream signaling molecules.

  • Cell surface receptor expression: Internalization of CXCR1/CXCR2.

• In vivo model adaptation:

  • For peritoneal neutrophil recruitment models, inject anti-CXCL8 antibody (30-300 μg) IP, followed 20 hours later by CXCL8 (300 μg) .

  • Evaluate outcomes 4 hours after CXCL8 challenge .

  • Always include appropriate controls (isotype antibody, PBS) .

• Data analysis and quantification:

  • Calculate percent inhibition relative to positive and negative controls.

  • Determine IC50 values for antibody potency.

  • Assess statistical significance using appropriate tests for your experimental design.

  • Consider constructing inhibition curves across multiple antibody concentrations.

• Potential pitfalls and controls:

  • Non-specific effects at high antibody concentrations.

  • Fc receptor-mediated effects (use F(ab')2 fragments to control for this).

  • Endotoxin contamination affecting cellular responses.

  • Receptor compensation or upregulation of alternative pathways.

How can I develop a reliable sandwich ELISA for quantifying CXCL8 in complex biological samples?

Developing a robust sandwich ELISA for CXCL8 requires methodical optimization of multiple parameters:

• Antibody pair selection:

  • Use validated antibody pairs known to recognize distinct, non-overlapping epitopes.

  • For example, Mouse Anti-Human IL-8/CXCL8 Monoclonal Antibody (MAB2081) as capture antibody and biotinylated Mouse Anti-Human IL-8/CXCL8 Monoclonal Antibody (MAB2082) as detection antibody have been validated together .

• Standard curve optimization:

  • Use recombinant human CXCL8 protein (Ser28-Ser99) as standard .

  • Prepare a 2-fold serial dilution series covering the expected range of sample concentrations .

  • Include a blank (buffer only) control.

• Plate coating process:

  • Optimize capture antibody concentration and coating buffer (typically carbonate/bicarbonate pH 9.5).

  • Determine optimal coating time and temperature (typically overnight at 4°C).

  • Ensure thorough washing with PBS containing 0.05% Tween-20.

• Blocking conditions:

  • Test different blocking buffers (BSA, casein, commercial formulations).

  • Optimize blocking time and temperature to minimize background while maintaining sensitivity.

• Sample preparation considerations:

  • For serum/plasma: Determine optimal dilution to minimize matrix effects.

  • For cell culture supernatants: Consider concentration methods for low-abundance samples.

  • For tissue extracts: Optimize homogenization and extraction buffers.

• Detection system optimization:

  • For biotinylated detection antibodies, optimize streptavidin-HRP concentration .

  • Determine optimal substrate incubation time to maximize signal while avoiding saturation.

  • Consider signal amplification systems for enhanced sensitivity.

• Validation parameters:

  Parameter	Acceptance Criteria	Test Method
  Sensitivity	LLOD < 10 pg/mL	Standard curve analysis
  Working Range	At least 2 logs	Linear portion of standard curve
  Precision	CV < 15%	Intra/inter-assay replicates
  Recovery	80-120%	Spike-in experiments
  Specificity	No cross-reactivity	Testing related chemokines
  Sample Stability	< 20% change	Freeze-thaw testing

• Troubleshooting common issues:

  • High background: Increase washing steps, optimize blocking, test different detection antibody concentrations.

  • Poor sensitivity: Try signal amplification systems, increase sample volume, optimize capture antibody.

  • Poor reproducibility: Standardize incubation times and temperatures, use automated wash systems.

Why might I observe discrepancies between CXCL8 protein detected by Western blot versus ELISA?

Discrepancies between Western blot and ELISA results for CXCL8 can arise from multiple factors:

• Detection of different molecular forms:

  • Western blot separates proteins by size, potentially distinguishing between different CXCL8 isoforms (72aa vs. 77aa) .

  • ELISA may detect all isoforms collectively, depending on the antibody pair's epitope specificity.

  • Post-translational modifications may affect antibody recognition differently in each method.

• Sample preparation differences:

  • Western blot typically involves denaturation, which may expose epitopes hidden in the native conformation.

  • ELISA generally detects native protein, potentially missing epitopes that require denaturation.

  • Reducing agents in Western blot samples may affect recognition of disulfide-dependent epitopes.

• Sensitivity and dynamic range variations:

  • ELISA typically offers greater sensitivity (often pg/mL range) compared to Western blot.

  • Western blot may detect protein aggregates or multimers that appear at different molecular weights.

  • Quantification accuracy differs significantly between the two methods.

• Protocol-specific considerations:

  • For Western blot: Cell lysis conditions, protein loading amount, transfer efficiency, and detection method all influence results.

  • For ELISA: Sample dilution, matrix effects, and standard curve fitting affect quantification.

• Antibody performance differences:

  • The same antibody may perform differently in each format due to epitope accessibility.

  • Different antibodies optimized for each technique may recognize distinct epitopes with varying affinity.

Methodological approach to resolve discrepancies:

• Perform both assays with the same samples prepared in parallel.

• Use multiple antibodies recognizing different epitopes.

• Include appropriate positive controls (e.g., recombinant CXCL8 protein).

• Consider alternative methods like mass spectrometry for unbiased protein identification.

• Correlate protein data with mRNA expression.

How can I differentiate between specific and non-specific binding when using anti-CXCL8 antibodies?

Establishing antibody specificity requires systematic control experiments:

• Essential experimental controls:

  • Isotype controls: Use antibodies of the same isotype, species, and concentration (e.g., IgG2a isotype for K097F7, IgG2b isotype for 152254) .

  • Antigen competition: Pre-incubate antibody with excess recombinant CXCL8 to block specific binding sites.

  • Stimulation controls: Compare expression in stimulated (e.g., PMA/LPS treatment) versus unstimulated cells .

  • Secondary-only controls: Omit primary antibody to assess secondary antibody background.

• Technique-specific validation approaches:

  • Western blot:

    • Look for a single band at the expected molecular weight (~8-11 kDa for CXCL8) .

    • Confirm band disappearance with competition controls.

  • Flow cytometry:

    • Compare signal to isotype control and unstained cells.

    • Calculate staining index to quantify signal-to-noise ratio.

    • Use fluorescence-minus-one controls for multi-color panels.

  • Immunohistochemistry/Immunofluorescence:

    • Include positive control tissues known to express CXCL8.

    • Evaluate subcellular localization patterns (consistent with secretory pathway).

    • Perform peptide competition controls.

  • ELISA:

    • Perform dilution linearity tests (serial dilutions should yield proportional results).

    • Conduct spike-and-recovery experiments to assess matrix effects.

• Cross-validation strategies:

  • Compare results across multiple techniques.

  • Correlate protein detection with mRNA expression.

  • Use multiple antibodies against different CXCL8 epitopes.

  • Perform knockdown/knockout validation where possible.

• Signal-to-background optimization:

  • Titrate antibody concentration to maximize specific signal while minimizing background.

  • Optimize blocking conditions (5% BSA, normal serum).

  • Include detergents in wash buffers (0.05-0.1% Tween-20).

  • For flow cytometry, use Fc receptor blocking reagents.

What experimental approaches can distinguish between the biological activities of different CXCL8 isoforms?

Distinguishing between CXCL8 isoforms (primarily the 72aa and 77aa forms) requires specialized experimental approaches:

• Isoform-specific detection strategies:

  • Mass spectrometry: Provides precise molecular weight determination and sequence analysis to differentiate isoforms.

  • Isoform-selective antibodies: Some antibodies may preferentially recognize specific isoforms based on N-terminal epitopes.

  • 2D gel electrophoresis: Can separate isoforms based on both molecular weight and isoelectric point differences.

• Functional comparison assays:

  • Neutrophil activation: IL-8(77) is reported to be a less potent neutrophil activator than other forms . Compare calcium flux, respiratory burst, or degranulation responses.

  • Chemotaxis assays: Compare migration of CXCR1/CXCR2-expressing cells (e.g., BaF3 transfected cells) in response to different isoforms .

  • Receptor binding studies: Compare binding affinity and kinetics of each isoform to CXCR1 versus CXCR2.

  • Angiogenesis models: IL-8(77) is present at high levels during fetal development, where it mediates angiogenesis rather than inflammation .

• Receptor signaling analysis:

  • Phosphorylation kinetics: Measure activation of downstream signaling molecules (ERK, p38, Akt).

  • Receptor internalization: Compare rates of CXCR1/CXCR2 internalization following stimulation.

  • Biased signaling: Determine if isoforms preferentially activate different signaling pathways.

• Experimental design considerations:

  • Use recombinant proteins representing specific isoforms.

  • Control for potential contamination between isoform preparations.

  • Include dose-response analyses as potency may differ.

  • Consider kinetic studies as response duration may vary.

• In vivo comparative studies:

  • Inflammatory models: Compare neutrophil recruitment efficiency.

  • Developmental models: Assess angiogenic potential.

  • Tumor models: Evaluate effects on tumor growth and metastasis.

• Data analysis approaches:

  • Determine EC50 values for different biological activities.

  • Calculate relative potencies between isoforms.

  • Consider area-under-curve analyses for kinetic differences.

What are the best practices for validating neutralizing anti-CXCL8 antibodies in in vivo models?

Validating neutralizing anti-CXCL8 antibodies for in vivo applications requires a comprehensive approach:

• Pre-in vivo characterization:

  • Confirm neutralizing activity in vitro using functional assays like chemotaxis inhibition.

  • Determine antibody affinity, specificity, and cross-reactivity.

  • Establish dose-response relationships and calculate ND50 values .

• Experimental design for in vivo validation:

  • Dose optimization: Test multiple doses (e.g., 30 μg, 100 μg, 300 μg as used in mouse models) .

  • Administration timing: For peritoneal neutrophil models, inject antibody 20 hours before CXCL8 challenge .

  • Route selection: Consider intraperitoneal (IP) for peritoneal models or intravenous (IV) for systemic effects .

  • Analysis timepoint: Evaluate outcomes at appropriate intervals (e.g., 4 hours post-CXCL8 challenge) .

• Essential controls:

  • Isotype controls: Use isotype-matched control antibodies at equivalent doses .

  • Vehicle controls: Include PBS-only treatments .

  • Positive controls: Include known CXCL8 pathway inhibitors when available.

  • Dose-matching: Ensure control antibodies are administered at the same concentration.

• Outcome measurements:

  Parameter	Method	Expected Result
  Neutrophil recruitment	Flow cytometry of peritoneal cells	Reduced neutrophil infiltration
  Inflammatory mediators	Multiplex cytokine analysis	Altered inflammatory profile
  Target engagement	Free vs. bound CXCL8 ELISA	Decreased free CXCL8
  Tissue effects	Histopathological assessment	Reduced inflammatory damage

• Pharmacokinetic/Pharmacodynamic considerations:

  • Determine antibody half-life in relevant tissues.

  • Assess tissue distribution.

  • Monitor duration of biological effect relative to antibody clearance.

  • Consider potential anti-drug antibody development in longer studies.

• Ethical and reporting standards:

  • Ensure compliance with institutional animal care guidelines.

  • All protocols should be reviewed and approved by institutional animal care committees .

  • Use appropriate statistical methods with adequate sample sizes.

  • Report according to ARRIVE guidelines.